Wedbush reaffirmed their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS - Free Report) in a research note released on Wednesday morning,RTT News reports. They currently have a $25.00 target price on the stock.
Several other brokerages have also recently issued reports on ITOS. Wells Fargo & Company decreased their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a report on Thursday, December 19th. HC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, January 16th.
View Our Latest Analysis on iTeos Therapeutics
iTeos Therapeutics Price Performance
ITOS stock traded down $0.04 on Wednesday, reaching $7.05. 287,485 shares of the company traded hands, compared to its average volume of 450,545. The firm has a fifty day simple moving average of $7.52 and a 200-day simple moving average of $9.42. The company has a market cap of $257.56 million, a P/E ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a one year low of $6.67 and a one year high of $18.75.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.13. On average, sell-side analysts forecast that iTeos Therapeutics will post -3.49 EPS for the current year.
Institutional Trading of iTeos Therapeutics
Institutional investors have recently made changes to their positions in the stock. BVF Inc. IL purchased a new position in shares of iTeos Therapeutics during the fourth quarter valued at approximately $17,856,000. JPMorgan Chase & Co. raised its stake in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after buying an additional 1,601,477 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of iTeos Therapeutics during the 4th quarter valued at $7,272,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of iTeos Therapeutics by 347.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock worth $7,082,000 after buying an additional 716,271 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of iTeos Therapeutics by 1,008.8% in the fourth quarter. Millennium Management LLC now owns 411,072 shares of the company's stock worth $3,157,000 after acquiring an additional 373,999 shares during the period. Hedge funds and other institutional investors own 97.16% of the company's stock.
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
